Hoth Therapeutics announces expansion of FDA cleared trial of HT-001

Hoth Therapeutics announced that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001. This First-in-Human Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitor. “We are very pleased to have received approval for our FIH clinical trial,” said Hoth Therapeutics Chief Executive Officer, Robb Knie. “We are hopeful that this trial will demonstrate successful delivery of our lead therapeutic candidate HT-001. Coupled with approval at Washington University of St. Louis and MD Anderson Cancer Center, University of Miami will be our third site approved to host our trial and bring hope to cancer patients suffering from skin toxicities associated with EGFRi treatments. I look forward to updating our investors and patients on this ongoing trial in the first quarter of 2024.”